{"id":14460,"date":"2025-12-22T07:55:00","date_gmt":"2025-12-22T13:55:00","guid":{"rendered":"https:\/\/visionshare.org\/?p=14460"},"modified":"2026-01-08T11:17:30","modified_gmt":"2026-01-08T17:17:30","slug":"faire-progresser-linnovation-dans-la-transplantation-de-la-cornee-klalpro","status":"publish","type":"post","link":"https:\/\/visionshare.org\/fr\/advancing-innovation-in-corneal-transplantation-klalpro\/","title":{"rendered":"Faire progresser l'innovation dans la transplantation corn\u00e9enne : Le point de vue du vice-pr\u00e9sident de la R&amp;D d'Eversight"},"content":{"rendered":"<p>Dans le cadre de <a href=\"https:\/\/visionshare.org\/fr\/\">Vision Share<\/a>\u2019Dans le cadre de la s\u00e9rie en cours sur les avanc\u00e9es dans le domaine de la transplantation de la corn\u00e9e, nous avons r\u00e9cemment rencontr\u00e9 des repr\u00e9sentants de la <strong><a href=\"http:\/\/member-list-info\/eversight-eye-bank\/\">Eversight\u2019<\/a>\u00e9sident de la recherche et du d, <\/strong><a href=\"http:\/\/linkedin.com\/in\/onkar-b-sawant\"><strong>Onkar B. Sawant, PhD<\/strong><\/a> pour discuter des innovations \u00e9mergentes qui fa\u00e7onnent l'avenir du secteur.<\/p>\n\n\n\n<p>Avec l'\u00e9clairage apport\u00e9 par le webinaire d'Eversight sur les th\u00e8mes suivants <strong>Dr. Edward Holland<\/strong> et <strong>Dr. Nambi Nallasamy<\/strong>, La conversation a mis en lumi\u00e8re la fa\u00e7on dont la science, la technologie et les solutions bas\u00e9es sur les banques d'yeux red\u00e9finissent ce qui est possible pour les patients du monde entier.<\/p>\n\n\n\n<p>Cet entretien s'inscrit dans le cadre des efforts d\u00e9ploy\u00e9s par Vision Share pour recueillir les points de vue des chercheurs, des concepteurs d'appareils, des chirurgiens et des banques d'yeux sur la mani\u00e8re dont l'innovation continue de transformer la transplantation de la corn\u00e9e.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Comment l'innovation chirurgicale remod\u00e8le les soins de la corn\u00e9e<\/strong><\/h2>\n\n\n\n<p>Au cours de la derni\u00e8re d\u00e9cennie, des techniques lamellaires post\u00e9rieures telles que le <strong><a href=\"\/fr\/services-de-traitement-des-tissus-de-transplantation\/\">DMEK<\/a><\/strong> sont devenues l'approche chirurgicale privil\u00e9gi\u00e9e dans des cas bien s\u00e9lectionn\u00e9s pour traiter les maladies endoth\u00e9liales en raison de leur temps de r\u00e9cup\u00e9ration plus rapide, de leur taux de rejet r\u00e9duit et de leurs r\u00e9sultats visuels sup\u00e9rieurs \u00e0 ceux de la PKP traditionnelle.<\/p>\n\n\n\n<p>Pour la chirurgie DMEK, des innovations telles que l'ajout d'un tampon \u201cS\u201d ou d'autres marques d'orientation pour faciliter le positionnement du greffon, ainsi que le pr\u00e9chargement du tissu DMEK dans les injecteurs pr\u00e9par\u00e9s par les banques oculaires, repr\u00e9sentent des avanc\u00e9es importantes qui am\u00e9liorent l'efficacit\u00e9 de l'insertion du greffon dans la chambre ant\u00e9rieure. Ensemble, ces am\u00e9liorations ont contribu\u00e9 \u00e0 faire de la DMEK une option chirurgicale de premier plan en cas de d\u00e9faillance endoth\u00e9liale standard dans les yeux pr\u00e9sentant une bonne visibilit\u00e9 de la chambre ant\u00e9rieure. \u00b9<\/p>\n\n\n\n<p>Ces progr\u00e8s, associ\u00e9s \u00e0 l'am\u00e9lioration de l'imagerie, aux technologies de guidage en salle d'op\u00e9ration et \u00e0 la pr\u00e9paration standardis\u00e9e des greffons dans les banques d'yeux, ont fait \u00e9voluer la chirurgie de la corn\u00e9e vers une discipline plus pr\u00e9visible et ax\u00e9e sur les r\u00e9sultats.<\/p>\n\n\n\n<p>Cependant, le Dr Sawant a fait remarquer que certaines des innovations les plus importantes ne sont pas toujours mesur\u00e9es en termes de volume. Elles apparaissent l\u00e0 o\u00f9 les besoins cliniques sont les plus urgents, en particulier dans le traitement des maladies infectieuses. <strong>d\u00e9ficit en cellules souches limbiques (CSL)<\/strong>, La maladie d'Alzheimer est une affection complexe, souvent d\u00e9bilitante, qui touche de mani\u00e8re disproportionn\u00e9e les patients des r\u00e9gions \u00e0 revenus faibles et moyens.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>KLAL-Pro : Une avanc\u00e9e dans le traitement du d\u00e9ficit en cellules souches limbiques<\/strong><\/h2>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\" style=\"grid-template-columns:21% auto\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"922\" height=\"1024\" src=\"https:\/\/visionshare.org\/wp-content\/uploads\/KLAL_Pro_Ill_FNL-922x1024.png\" alt=\"\" class=\"wp-image-14462 size-large\" srcset=\"https:\/\/visionshare.org\/wp-content\/uploads\/KLAL_Pro_Ill_FNL-922x1024.png 922w, https:\/\/visionshare.org\/wp-content\/uploads\/KLAL_Pro_Ill_FNL-270x300.png 270w, https:\/\/visionshare.org\/wp-content\/uploads\/KLAL_Pro_Ill_FNL-768x853.png 768w, https:\/\/visionshare.org\/wp-content\/uploads\/KLAL_Pro_Ill_FNL-11x12.png 11w, https:\/\/visionshare.org\/wp-content\/uploads\/KLAL_Pro_Ill_FNL.png 1314w\" sizes=\"auto, (max-width: 922px) 100vw, 922px\" \/><\/figure><div class=\"wp-block-media-text__content\">\n<p>L'un des sujets les plus importants de notre discussion a \u00e9t\u00e9 le d\u00e9veloppement par Eversight de KLAL-Pro, une allogreffe k\u00e9ratolimbale d'\u00e9paisseur partielle pr\u00e9par\u00e9e par une banque ophtalmologique et enrichie de cellules souches \u00e9pith\u00e9liales limbiques. En avril 2025, Eversight d\u00e9clarait \u00eatre la seule banque ophtalmologique \u00e0 pr\u00e9parer le tissu KLAL-Pro, une allogreffe k\u00e9ratolimbale pr\u00eate \u00e0 l'emploi con\u00e7ue pour r\u00e9duire la variabilit\u00e9 de la pr\u00e9paration du tissu et r\u00e9duire de mani\u00e8re significative le temps de la chirurgie. <sup>2<\/sup><\/p>\n\n\n\n<p>KLAL-Pro est :<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Personnalisable (jusqu'\u00e0 180\u00b0 du limbe du donneur, 200-300 \u03bcm d'\u00e9paisseur). <sup>3<\/sup><\/li>\n\n\n\n<li>Pr\u00e9par\u00e9 selon un protocole contr\u00f4l\u00e9 et v\u00e9rifi\u00e9 par OCT <sup>2<\/sup><\/li>\n\n\n\n<li>Con\u00e7u pour pr\u00e9server les palissades de Vogt, y compris la niche limbique <sup>2<\/sup><\/li>\n\n\n\n<li>Optimis\u00e9 pour prendre en charge les cas de LSCD unilat\u00e9raux et bilat\u00e9raux <sup>3<\/sup><\/li>\n\n\n\n<li>Peut \u00eatre utilis\u00e9 efficacement pour les proc\u00e9dures de Cincinnati et de Cincinnati modifi\u00e9 <sup>5<\/sup> <sup>6<\/sup><\/li>\n<\/ul>\n<\/div><\/div>\n\n\n\n<p>Les premi\u00e8res exp\u00e9riences cliniques le sugg\u00e8rent :<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Expansion robuste des cellules souches limbiques et r\u00e9\u00e9pith\u00e9lialisation <sup>2<\/sup><\/li>\n\n\n\n<li>R\u00e9duction significative de la dur\u00e9e de l'intervention chirurgicale par rapport \u00e0 la m\u00e9thode traditionnelle KLAL seule <sup>2<\/sup><\/li>\n\n\n\n<li>Durabilit\u00e9 et potentiel de r\u00e9g\u00e9n\u00e9ration qui favorisent la stabilit\u00e9 \u00e0 long terme <sup>2<\/sup><\/li>\n<\/ul>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\" style=\"grid-template-columns:20% auto\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"630\" height=\"700\" src=\"https:\/\/visionshare.org\/wp-content\/uploads\/Physicians_Services_Page_KLAL-Pro.png\" alt=\"\" class=\"wp-image-14465 size-full\" srcset=\"https:\/\/visionshare.org\/wp-content\/uploads\/Physicians_Services_Page_KLAL-Pro.png 630w, https:\/\/visionshare.org\/wp-content\/uploads\/Physicians_Services_Page_KLAL-Pro-270x300.png 270w, https:\/\/visionshare.org\/wp-content\/uploads\/Physicians_Services_Page_KLAL-Pro-11x12.png 11w\" sizes=\"auto, (max-width: 630px) 100vw, 630px\" \/><\/figure><div class=\"wp-block-media-text__content\">\n<p>Les chirurgiens se font l'\u00e9cho de sa valeur. Comme le Dr Nambi Nallasamy, co-cr\u00e9ateur de KLAL-Pro, l'a partag\u00e9 :<\/p>\n\n\n\n<p><em>\u201cLes greffons KLAL-Pro minimisent l'exc\u00e8s de tissu stromal et rationalisent la transplantation de cellules souches de la surface oculaire. Avec une immunosuppression appropri\u00e9e, mes patients ont obtenu d'excellents r\u00e9sultats\u201d.\u201d<\/em> <sup>3<\/sup><\/p>\n<\/div><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Aper\u00e7u du r\u00e9cent webinaire d'Eversight : Moderniser les soins en LSCD<\/strong><\/h2>\n\n\n\n<p>Au cours de la <a href=\"https:\/\/eversightvision.org\/blog\/klal-pro-limbal-stem-cell-deficiency-advances-in-lscd-management\">Novembre 2025 S\u00e9minaire web d'Eversight sur la gestion des LSCD<\/a>, Holland et Nallasamy ont soulign\u00e9 le besoin urgent d'une sensibilisation et d'une adoption plus larges des interventions chirurgicales fond\u00e9es sur des donn\u00e9es probantes. De nombreux patients atteints de LSCD totale continuent de subir des k\u00e9ratoplasties p\u00e9n\u00e9trantes, malgr\u00e9 les r\u00e9sultats m\u00e9diocres de la PKP en pr\u00e9sence d'une d\u00e9faillance compl\u00e8te des cellules souches limbiques.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Les principaux enseignements de ce webinaire sont les suivants :<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>1. Un diagnostic pr\u00e9cis de la LSCD est essentiel<\/strong><\/h3>\n\n\n\n<p>Le LSCD pr\u00e9sente un \u00e9ventail de signes - n\u00e9ovascularisation, conjonctivalisation, d\u00e9fauts \u00e9pith\u00e9liaux persistants - et doit \u00eatre \u00e9valu\u00e9 \u00e0 l'aide d'un examen clinique, d'une cytologie d'empreinte, d'une microscopie confocale ou d'un AS-OCT.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>2. Le choix de la proc\u00e9dure doit correspondre \u00e0 la gravit\u00e9 de la maladie<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Maladie unilat\u00e9rale :<\/strong> autogreffe conjonctivo-limbaire (CLAU) <sup>4<\/sup><\/li>\n\n\n\n<li><strong>Maladie bilat\u00e9rale :<\/strong> KLAL ou un <strong>Proc\u00e9dure Cincinnati<\/strong>, qui combine le tissu vivant avec le KLAL pour fournir une couverture limbique \u00e0 360\u00b0. <sup>5<\/sup> <sup>6<\/sup><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>3. L'immunosuppression est essentielle, plus facile \u00e0 g\u00e9rer et plus s\u00fbre qu'on ne le croit.<\/strong><\/h3>\n\n\n\n<p>En utilisant des protocoles inspir\u00e9s de la transplantation r\u00e9nale, l'immunosuppression syst\u00e9mique \u00e0 long terme augmente consid\u00e9rablement la survie du greffon. Il est important de noter qu'aucun d\u00e9c\u00e8s n'a \u00e9t\u00e9 signal\u00e9 dans des centaines de cas chirurgicaux de LSCD <sup>7<\/sup>, La s\u00e9curit\u00e9 de la th\u00e9rapie syst\u00e9mique a \u00e9t\u00e9 longtemps mal per\u00e7ue.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>4. KLAL-Pro r\u00e9duit le temps et la complexit\u00e9 des op\u00e9rations chirurgicales<\/strong><\/h3>\n\n\n\n<p>L'un des principaux obstacles \u00e0 la chirurgie du LSCD a \u00e9t\u00e9 le fardeau technique de la dissection du tissu KLAL. La pr\u00e9paration des banques d'yeux d\u00e9place cette charge de travail en amont, ce qui permet \u00e0 un plus grand nombre de chirurgiens d'effectuer une reconstruction LSCD en toute confiance.<\/p>\n\n\n\n<p>Ces informations fournissent un contexte important pour comprendre la place du KLAL-Pro et d'autres innovations dans le cadre des soins modernes du LSCD.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>Au-del\u00e0 des tissus : La prochaine \u00e9tape de l'innovation<\/strong><\/h5>\n\n\n\n<p>Notre conversation avec le Dr Sawant a mis en lumi\u00e8re plusieurs domaines \u00e9mergents qui promettent de remodeler la transplantation de la corn\u00e9e :<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>Th\u00e9rapies cellulaires<\/strong><\/h5>\n\n\n\n<p>Des cellules endoth\u00e9liales cultiv\u00e9es associ\u00e9es \u00e0 des inhibiteurs de la Rho Kinase (ROCK) pourraient un jour r\u00e9duire compl\u00e8tement la d\u00e9pendance \u00e0 l'\u00e9gard des tissus des donneurs. Les premiers r\u00e9sultats des essais men\u00e9s au Japon et aux \u00c9tats-Unis sont tr\u00e8s prometteurs.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>IA et imagerie avanc\u00e9e<\/strong><\/h5>\n\n\n\n<p>Les outils pr\u00e9dictifs pour la survie du greffon et la s\u00e9lection du donneur, ainsi que l'OCT perop\u00e9ratoire, r\u00e9duisent la variabilit\u00e9 et am\u00e9liorent la pr\u00e9cision.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>Supports de stockage am\u00e9lior\u00e9s<\/strong><\/h5>\n\n\n\n<p>De nouvelles solutions, telles que les milieux \u00e0 dur\u00e9e de vie prolong\u00e9e valid\u00e9s dans les \u00e9tudes Eversight, peuvent accro\u00eetre la flexibilit\u00e9 logistique et l'acc\u00e8s aux tissus \u00e0 l'\u00e9chelle mondiale.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>Ing\u00e9nierie tissulaire et bioscaffolds<\/strong><\/h5>\n\n\n\n<p>Les matrices synth\u00e9tiques ou d\u00e9cellularis\u00e9es pourraient \u00e9ventuellement permettre la restauration de la corn\u00e9e lorsque le tissu donneur est rare.<\/p>\n\n\n\n<p>Pour en savoir plus sur ces innovations et sur d'autres sujets, lisez le point de vue du Dr Sawant, <a href=\"https:\/\/eversightvision.org\/blog\/how-research-development-are-enhancing-corneal-transplantation\"><em>Au-del\u00e0 du tissu : Comment la recherche et le d\u00e9veloppement am\u00e9liorent la transplantation de la corn\u00e9e<\/em><\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Une mission commune : \u00c9largir la bo\u00eete \u00e0 outils chirurgicale<\/strong><\/h2>\n\n\n\n<p>Le point de vue le plus pertinent est peut-\u00eatre celui du Dr Onkar Sawant, qui a pr\u00e9sent\u00e9 l'opportunit\u00e9 collective du domaine :<\/p>\n\n\n\n<p><em>\u201cNotre objectif devrait \u00eatre de fournir davantage d'outils aux chirurgiens et aux ophtalmologistes du monde entier. Toute innovation ne doit pas \u00eatre consid\u00e9r\u00e9e comme une menace pour les banques d'yeux, mais comme une opportunit\u00e9 d'\u00e9largir notre impact dans la lutte contre la c\u00e9cit\u00e9.\u201d<\/em><\/p>\n\n\n\n<p>Cette philosophie s'aligne sur l'accent mis par Vision Share sur la collaboration, l'acc\u00e8s mondial et l'offre aux chirurgiens d'options de restauration de la vue adapt\u00e9es aux besoins de leurs patients. <strong><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>L'innovation prosp\u00e8re lorsque nous travaillons ensemble<\/strong><\/h2>\n\n\n\n<p>Notre conversation avec Eversight - et les id\u00e9es partag\u00e9es dans le cadre de l'enqu\u00eate sur la s\u00e9curit\u00e9 des produits de consommation - nous a permis d'obtenir des informations sur la s\u00e9curit\u00e9 des produits. <a href=\"https:\/\/eversightvision.org\/eversight-academy\">Acad\u00e9mie Eversight<\/a> mettent en \u00e9vidence un th\u00e8me constant : l'avenir de la transplantation corn\u00e9enne d\u00e9pend de la collaboration.<\/p>\n\n\n\n<p>Les banques oculaires, les chirurgiens, les chercheurs et les d\u00e9veloppeurs de technologies jouent tous un r\u00f4le essentiel dans l'am\u00e9lioration de l'acc\u00e8s, de la s\u00e9curit\u00e9 et des r\u00e9sultats. Qu'il s'agisse d'avanc\u00e9es comme le DMEK, de perc\u00e9es comme le KLAL-Pro ou de th\u00e9rapies cellulaires \u00e9mergentes, l'innovation continue de repousser les limites de la restauration de la vue. Vision Share est fier de contribuer \u00e0 rassembler ces perspectives et de les partager avec la communaut\u00e9 internationale.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>R\u00e9f\u00e9rences<\/strong><\/h2>\n\n\n\n<p>1.   Panel de l'Acad\u00e9mie am\u00e9ricaine d'ophtalmologie sur la corn\u00e9e et les maladies externes. Mod\u00e8le de pratique pr\u00e9f\u00e9r\u00e9e pour l'\u0153d\u00e8me corn\u00e9en et l'opacification\u00ae. <em>Acad\u00e9mie am\u00e9ricaine d'ophtalmologie.<\/em> 2023.<br><a href=\"https:\/\/www.aao.org\/education\/preferred-practice-pattern\/corneal-edema-opacification-ppp-2023\">https:\/\/www.aao.org\/education\/preferred-practice-pattern\/corneal-edema-opacification-ppp-2023<\/a><\/p>\n\n\n\n<p>2.    Eversight. <em>KLAL-Pro : Offres et services en mati\u00e8re de tissus<\/em>. Eversight ; consult\u00e9 en d\u00e9cembre 2025. <a href=\"https:\/\/eversightvision.org\/surgeons\/tissue-offerings-services\/klal-pro?utm_source=chatgpt.com\">https:\/\/eversightvision.org\/surgeons\/tissue-offerings-services\/klal-pro<\/a><\/p>\n\n\n\n<p>3.    Eversight. <em>KLAL-Pro : Une avanc\u00e9e dans le traitement du d\u00e9ficit en cellules souches limbiques (CSL)<\/em>. Eversight Blog ; consult\u00e9 en d\u00e9cembre 2025.<br><a href=\"https:\/\/eversightvision.org\/blog\/klal-pro-a-breakthrough-in-treating-limbal-stem-cell-deficiency-lscd?utm_source=chatgpt.com\">https:\/\/eversightvision.org\/blog\/klal-pro-a-breakthrough-in-treating-limbal-stem-cell-deficiency-lscd<\/a><\/p>\n\n\n\n<p>4.    Acad\u00e9mie Eversight. <em>Une approche compl\u00e8te du d\u00e9ficit en cellules souches limbiques : KLAL-Pro et strat\u00e9gies de prise en charge postop\u00e9ratoire.<\/em> YouTube ; publi\u00e9 en 2025. https:\/\/www.youtube.com\/watch?v=FHBJpstGkWg&amp;t=4s<\/p>\n\n\n\n<p>5.    Biber, Joseph M MD ; Skeens, Heather M MD ; Neff, Kristiana D MD ; Holland, Edward J MD. The Cincinnati Procedure : Technique and Outcomes of Combined Living-Related Conjunctival Limbal Allografts and Keratolimbal Allografts in Severe Ocular Surface Failure. Cornea 30(7):p 765-771, juillet 2011. | DOI : 10.1097\/ICO.0b013e318201467c<\/p>\n\n\n\n<p>6.    Chan, Clara C. MD, FRCSC*,\u2020 ; Biber, Joseph M. MD\u2021 ; Holland, Edward J. MD*,\u2020. La proc\u00e9dure modifi\u00e9e de Cincinnati : Autogreffes de limbe conjonctival et allogreffes de k\u00e9ratolimbe combin\u00e9es en cas d'\u00e9chec s\u00e9v\u00e8re de la surface oculaire unilat\u00e9rale. Cornea 31(11):p 1264-1272, novembre 2012. | DOI : 10.1097\/ICO.0b013e31823f8e95<\/p>\n\n\n\n<p>7.   Holland EJ, Mogilishetty G, Skeens HM, Hair DB, Neff KD, Biber JM, Chan CC.<br>Immunosuppression syst\u00e9mique dans la transplantation de cellules souches de la surface oculaire : r\u00e9sultats d'une exp\u00e9rience de 10 ans. <em>Ophtalmologie.<\/em> 2012;119(4):651\u2013658. doi:10.1016\/j.ophtha.2011.09.045. PMID : 22333664.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">\u00c0 propos de Vision Share<\/h2>\n\n\n\n<p><strong>Vision Share<\/strong>&nbsp;est une organisation \u00e0 but non lucratif de type 501(c)(3) et repr\u00e9sente avec fiert\u00e9 la&nbsp;<strong><a href=\"https:\/\/visionshare.org\/fr\/\">le plus grand r\u00e9seau de banques d'yeux au monde<\/a><\/strong>. Chaque banque oculaire membre est&nbsp;<strong>certifi\u00e9 par l'Eye Bank Association of America (EBAA) et par l'Association des banques de l'\u0153il d'Am\u00e9rique.<\/strong>&nbsp;<strong>enregistr\u00e9 aupr\u00e8s de la Food and Drug Administration (administration des denr\u00e9es alimentaires et des m\u00e9dicaments)&nbsp;<\/strong>(FDA). Guid\u00e9e par une vision commune, Vision Share met en commun ses ressources pour fournir aux chirurgiens des tissus oculaires fiables, de haute qualit\u00e9 et adapt\u00e9s \u00e0 leurs besoins sp\u00e9cifiques.&nbsp;<strong>Le r\u00e9seau Vision Share a fourni plus de 141 000 corn\u00e9es dans le monde entier, transformant des vies et redonnant la vue.<\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Dans le cadre de la s\u00e9rie Vision Share consacr\u00e9e aux avanc\u00e9es dans le domaine de la greffe de corn\u00e9e, nous avons r\u00e9cemment rencontr\u00e9 le vice-pr\u00e9sident de la recherche et du d\u00e9veloppement d'Eversight, Onkar B. ... <a title=\"Faire progresser l&#039;innovation dans la transplantation corn\u00e9enne : Le point de vue du vice-pr\u00e9sident de la R&amp;D d&#039;Eversight\" class=\"read-more\" href=\"https:\/\/visionshare.org\/fr\/advancing-innovation-in-corneal-transplantation-klalpro\/\" aria-label=\"En savoir plus sur Faire progresser l&#039;innovation dans la transplantation corn\u00e9enne : Le point de vue du vice-pr\u00e9sident de la R&amp;D d&#039;Eversight\">Lire plus<\/a><\/p>","protected":false},"author":1,"featured_media":14462,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[115],"tags":[],"class_list":["post-14460","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-corneal-transplant-innovation","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Advancing Innovation in Corneal Transplantation: Insights from Eversight\u2019s VP of R&amp;D - Vision Share<\/title>\n<meta name=\"description\" content=\"One of the most significant topics in our discussion was Eversight\u2019s development of KLAL-Pro. Read more about KLAL-Pro now.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/visionshare.org\/fr\/faire-progresser-linnovation-dans-la-transplantation-de-la-cornee-klalpro\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Advancing Innovation in Corneal Transplantation: Insights from Eversight\u2019s VP of R&amp;D - Vision Share\" \/>\n<meta property=\"og:description\" content=\"One of the most significant topics in our discussion was Eversight\u2019s development of KLAL-Pro. Read more about KLAL-Pro now.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/visionshare.org\/fr\/faire-progresser-linnovation-dans-la-transplantation-de-la-cornee-klalpro\/\" \/>\n<meta property=\"og:site_name\" content=\"Vision Share\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/visionshareinc\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-22T13:55:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-08T17:17:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/visionshare.org\/wp-content\/uploads\/KLAL_Pro_Ill_FNL.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1314\" \/>\n\t<meta property=\"og:image:height\" content=\"1460\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Vision Share\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Vision_Share\" \/>\n<meta name=\"twitter:site\" content=\"@Vision_Share\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Vision Share\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/visionshare.org\\\/advancing-innovation-in-corneal-transplantation-klalpro\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/visionshare.org\\\/advancing-innovation-in-corneal-transplantation-klalpro\\\/\"},\"author\":{\"name\":\"Vision Share\",\"@id\":\"https:\\\/\\\/visionshare.org\\\/#\\\/schema\\\/person\\\/e9185bca0894dad1d8ac2ee392f83b3b\"},\"headline\":\"Advancing Innovation in Corneal Transplantation: Insights from Eversight\u2019s VP of R&amp;D\",\"datePublished\":\"2025-12-22T13:55:00+00:00\",\"dateModified\":\"2026-01-08T17:17:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/visionshare.org\\\/advancing-innovation-in-corneal-transplantation-klalpro\\\/\"},\"wordCount\":1322,\"publisher\":{\"@id\":\"https:\\\/\\\/visionshare.org\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/visionshare.org\\\/advancing-innovation-in-corneal-transplantation-klalpro\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/visionshare.org\\\/wp-content\\\/uploads\\\/KLAL_Pro_Ill_FNL.png\",\"articleSection\":[\"Corneal transplant innovation\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/visionshare.org\\\/advancing-innovation-in-corneal-transplantation-klalpro\\\/\",\"url\":\"https:\\\/\\\/visionshare.org\\\/advancing-innovation-in-corneal-transplantation-klalpro\\\/\",\"name\":\"Advancing Innovation in Corneal Transplantation: Insights from Eversight\u2019s VP of R&amp;D - Vision Share\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/visionshare.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/visionshare.org\\\/advancing-innovation-in-corneal-transplantation-klalpro\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/visionshare.org\\\/advancing-innovation-in-corneal-transplantation-klalpro\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/visionshare.org\\\/wp-content\\\/uploads\\\/KLAL_Pro_Ill_FNL.png\",\"datePublished\":\"2025-12-22T13:55:00+00:00\",\"dateModified\":\"2026-01-08T17:17:30+00:00\",\"description\":\"One of the most significant topics in our discussion was Eversight\u2019s development of KLAL-Pro. Read more about KLAL-Pro now.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/visionshare.org\\\/advancing-innovation-in-corneal-transplantation-klalpro\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/visionshare.org\\\/advancing-innovation-in-corneal-transplantation-klalpro\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/visionshare.org\\\/advancing-innovation-in-corneal-transplantation-klalpro\\\/#primaryimage\",\"url\":\"https:\\\/\\\/visionshare.org\\\/wp-content\\\/uploads\\\/KLAL_Pro_Ill_FNL.png\",\"contentUrl\":\"https:\\\/\\\/visionshare.org\\\/wp-content\\\/uploads\\\/KLAL_Pro_Ill_FNL.png\",\"width\":1314,\"height\":1460},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/visionshare.org\\\/advancing-innovation-in-corneal-transplantation-klalpro\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/visionshare.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Advancing Innovation in Corneal Transplantation: Insights from Eversight\u2019s VP of R&amp;D\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/visionshare.org\\\/#website\",\"url\":\"https:\\\/\\\/visionshare.org\\\/\",\"name\":\"Vision Share\",\"description\":\"Your Trusted Source\",\"publisher\":{\"@id\":\"https:\\\/\\\/visionshare.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/visionshare.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/visionshare.org\\\/#organization\",\"name\":\"Vision Share\",\"url\":\"https:\\\/\\\/visionshare.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/visionshare.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/visionshare.org\\\/wp-content\\\/uploads\\\/cropped-cropped-cropped-VS_Your-trusted-source-logo-01-PNG.png\",\"contentUrl\":\"https:\\\/\\\/visionshare.org\\\/wp-content\\\/uploads\\\/cropped-cropped-cropped-VS_Your-trusted-source-logo-01-PNG.png\",\"width\":1655,\"height\":861,\"caption\":\"Vision Share\"},\"image\":{\"@id\":\"https:\\\/\\\/visionshare.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/visionshareinc\",\"https:\\\/\\\/x.com\\\/Vision_Share\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/visionsshare\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/visionshare.org\\\/#\\\/schema\\\/person\\\/e9185bca0894dad1d8ac2ee392f83b3b\",\"name\":\"Vision Share\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Faire progresser l'innovation dans la transplantation corn\u00e9enne : Le point de vue du vice-pr\u00e9sident de la R&amp;D d'Eversight - Vision Share","description":"L'un des sujets les plus importants de notre discussion a \u00e9t\u00e9 le d\u00e9veloppement de KLAL-Pro par Eversight. Pour en savoir plus sur KLAL-Pro, cliquez ici.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/visionshare.org\/fr\/faire-progresser-linnovation-dans-la-transplantation-de-la-cornee-klalpro\/","og_locale":"fr_FR","og_type":"article","og_title":"Advancing Innovation in Corneal Transplantation: Insights from Eversight\u2019s VP of R&amp;D - Vision Share","og_description":"One of the most significant topics in our discussion was Eversight\u2019s development of KLAL-Pro. Read more about KLAL-Pro now.","og_url":"https:\/\/visionshare.org\/fr\/faire-progresser-linnovation-dans-la-transplantation-de-la-cornee-klalpro\/","og_site_name":"Vision Share","article_publisher":"https:\/\/www.facebook.com\/visionshareinc","article_published_time":"2025-12-22T13:55:00+00:00","article_modified_time":"2026-01-08T17:17:30+00:00","og_image":[{"width":1314,"height":1460,"url":"https:\/\/visionshare.org\/wp-content\/uploads\/KLAL_Pro_Ill_FNL.png","type":"image\/png"}],"author":"Vision Share","twitter_card":"summary_large_image","twitter_creator":"@Vision_Share","twitter_site":"@Vision_Share","twitter_misc":{"\u00c9crit par":"Vision Share","Dur\u00e9e de lecture estim\u00e9e":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/visionshare.org\/advancing-innovation-in-corneal-transplantation-klalpro\/#article","isPartOf":{"@id":"https:\/\/visionshare.org\/advancing-innovation-in-corneal-transplantation-klalpro\/"},"author":{"name":"Vision Share","@id":"https:\/\/visionshare.org\/#\/schema\/person\/e9185bca0894dad1d8ac2ee392f83b3b"},"headline":"Advancing Innovation in Corneal Transplantation: Insights from Eversight\u2019s VP of R&amp;D","datePublished":"2025-12-22T13:55:00+00:00","dateModified":"2026-01-08T17:17:30+00:00","mainEntityOfPage":{"@id":"https:\/\/visionshare.org\/advancing-innovation-in-corneal-transplantation-klalpro\/"},"wordCount":1322,"publisher":{"@id":"https:\/\/visionshare.org\/#organization"},"image":{"@id":"https:\/\/visionshare.org\/advancing-innovation-in-corneal-transplantation-klalpro\/#primaryimage"},"thumbnailUrl":"https:\/\/visionshare.org\/wp-content\/uploads\/KLAL_Pro_Ill_FNL.png","articleSection":["Corneal transplant innovation"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/visionshare.org\/advancing-innovation-in-corneal-transplantation-klalpro\/","url":"https:\/\/visionshare.org\/advancing-innovation-in-corneal-transplantation-klalpro\/","name":"Faire progresser l'innovation dans la transplantation corn\u00e9enne : Le point de vue du vice-pr\u00e9sident de la R&amp;D d'Eversight - Vision Share","isPartOf":{"@id":"https:\/\/visionshare.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/visionshare.org\/advancing-innovation-in-corneal-transplantation-klalpro\/#primaryimage"},"image":{"@id":"https:\/\/visionshare.org\/advancing-innovation-in-corneal-transplantation-klalpro\/#primaryimage"},"thumbnailUrl":"https:\/\/visionshare.org\/wp-content\/uploads\/KLAL_Pro_Ill_FNL.png","datePublished":"2025-12-22T13:55:00+00:00","dateModified":"2026-01-08T17:17:30+00:00","description":"L'un des sujets les plus importants de notre discussion a \u00e9t\u00e9 le d\u00e9veloppement de KLAL-Pro par Eversight. Pour en savoir plus sur KLAL-Pro, cliquez ici.","breadcrumb":{"@id":"https:\/\/visionshare.org\/advancing-innovation-in-corneal-transplantation-klalpro\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/visionshare.org\/advancing-innovation-in-corneal-transplantation-klalpro\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/visionshare.org\/advancing-innovation-in-corneal-transplantation-klalpro\/#primaryimage","url":"https:\/\/visionshare.org\/wp-content\/uploads\/KLAL_Pro_Ill_FNL.png","contentUrl":"https:\/\/visionshare.org\/wp-content\/uploads\/KLAL_Pro_Ill_FNL.png","width":1314,"height":1460},{"@type":"BreadcrumbList","@id":"https:\/\/visionshare.org\/advancing-innovation-in-corneal-transplantation-klalpro\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/visionshare.org\/"},{"@type":"ListItem","position":2,"name":"Advancing Innovation in Corneal Transplantation: Insights from Eversight\u2019s VP of R&amp;D"}]},{"@type":"WebSite","@id":"https:\/\/visionshare.org\/#website","url":"https:\/\/visionshare.org\/","name":"Vision Share","description":"Votre source de confiance","publisher":{"@id":"https:\/\/visionshare.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/visionshare.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/visionshare.org\/#organization","name":"Vision Share","url":"https:\/\/visionshare.org\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/visionshare.org\/#\/schema\/logo\/image\/","url":"https:\/\/visionshare.org\/wp-content\/uploads\/cropped-cropped-cropped-VS_Your-trusted-source-logo-01-PNG.png","contentUrl":"https:\/\/visionshare.org\/wp-content\/uploads\/cropped-cropped-cropped-VS_Your-trusted-source-logo-01-PNG.png","width":1655,"height":861,"caption":"Vision Share"},"image":{"@id":"https:\/\/visionshare.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/visionshareinc","https:\/\/x.com\/Vision_Share","https:\/\/www.linkedin.com\/company\/visionsshare\/"]},{"@type":"Person","@id":"https:\/\/visionshare.org\/#\/schema\/person\/e9185bca0894dad1d8ac2ee392f83b3b","name":"Vision Share"}]}},"_links":{"self":[{"href":"https:\/\/visionshare.org\/fr\/wp-json\/wp\/v2\/posts\/14460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/visionshare.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/visionshare.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/visionshare.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/visionshare.org\/fr\/wp-json\/wp\/v2\/comments?post=14460"}],"version-history":[{"count":8,"href":"https:\/\/visionshare.org\/fr\/wp-json\/wp\/v2\/posts\/14460\/revisions"}],"predecessor-version":[{"id":14536,"href":"https:\/\/visionshare.org\/fr\/wp-json\/wp\/v2\/posts\/14460\/revisions\/14536"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/visionshare.org\/fr\/wp-json\/wp\/v2\/media\/14462"}],"wp:attachment":[{"href":"https:\/\/visionshare.org\/fr\/wp-json\/wp\/v2\/media?parent=14460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/visionshare.org\/fr\/wp-json\/wp\/v2\/categories?post=14460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/visionshare.org\/fr\/wp-json\/wp\/v2\/tags?post=14460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}